Integrin subunit as surrogate marker for MS relapse

The anti-α4-integrin monoclonal antibody natalizumab (Tysabri) is effective in most patients in treating multiple sclerosis (MS), but a percentage of people develop infusion reactions or stop responding because they develop neutralizing antibodies, and some people may have neutralizing antibodies without symptoms. Expression of CD49d, a subunit of α4-integrin on peripheral blood mononuclear cells (PBMCs) fall with successful treatment. French researchers looked at a group of people with relapsing-remitting MS, and found that levels of CD49d expression rise early or do not fall in patients with neutralizing antibodies--this could be used as a surrogate biomarker of natalizumab efficacy. Abstract

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.